Close menu

November 24th, 2022 | 12:40 CET

New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

  • Mining
  • Commodities
  • Biotechnology
  • chemicals
Photo credits:

As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BASF SE NA O.N. | DE000BASF111 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , Manuka Resources Limited | AU0000090292

Table of contents:

    Manuka Ressources: Facing a revaluation due to vanadium project?

    Manuka Ressources is certainly not known to many investors in this country. But the gold and silver producer is worth a look. Why? For one, Manuka has two projects - Wonawinta Silver and Mt Boppy Gold - that are already in production. They are now the largest silver producer in Australia. In the last fiscal year (ended June 30), Manuka generated revenue of AUD 53.5 million and a positive operating cash flow of AUD 8.9 million. There should be new data on Mt Boppy in the first quarter of 2023. On this basis, a decision on a production expansion will be made later in the year.

    In addition to the profitable operating business, Manuka took advantage of an opportunity in the summer of 2022 and secured an exciting project in New Zealand: the South Taranaki Bight project (STB project). This project is a VTM (vanadium-titanium-magnetite) iron sands project. It is said to have a resource potential of 3.8 billion tons. A preliminary feasibility study is already available, and the potential annual vanadium production is estimated at 55 million pounds. This could make it the world's third-largest vanadium producer after China and Russia. Vanadium is a relatively unknown metal, but all the more important. Among other things, it is needed for batteries and is, therefore, an important element for the energy transition. It is, therefore, not surprising that it is counted among the critical raw materials by the US, the EU and Australia. On the stock market - the share is also traded in Frankfurt - Manuka is currently valued at AUD 72 million. That is not too much, given the Company's profitable core business and the importance of vanadium. Those interested should note December 7, 2022, in their calendars. The Company will then present at the 5th IIF online investor conference. Participation is free for interested investors (click here to register

    BioNTech: Newsflow in sight

    With a market capitalization of EUR 38 billion, BioNTech naturally plays in a different league. But for the German biotech star, things have been anything but good on the stock market this year. From EUR 212 at the start of the year, the share price fell to EUR 123 within a few weeks. Since then, the share price has moved sideways with significant upward and downward fluctuations. Since the end of October, the mood has improved considerably, and the share is again trading above EUR 150. The reason: investors are increasingly focusing on the development pipeline of the Mainz-based company. And this is full to bursting.

    Thanks to the billions in profits from the COVID-19 vaccine, the Mainz-based company can go full throttle with development, especially in cancer research. The pipeline currently comprises 19 product candidates in 24 ongoing clinical trials. Accordingly, there should be a tidy newsflow at the Mainz-based company in the coming year. BioNTech, for example, has announced new data from up to 10 clinical trials for 2023.

    And, of course, there is the ongoing revenue from the COVID-19 vaccine - even if it is declining. In the current year, revenue is expected to be in the range of EUR 16 to 17 billion. At the end of the third quarter, BioNTech already had a bulging treasury. The Company had EUR 13.4 billion in cash and cash equivalents. In addition, a large part of the EUR 7.3 billion in trade receivables outstanding at the reporting date had already been received. As a result, the Company is fully financed for the coming years. To put this in perspective: in the current year, costs for research, sales/administration and capital expenditures total a maximum of EUR 2.6 billion.

    BASF: Analysts cautious

    Fundamentally, BASF is currently favorably valued. Despite the turmoil on the energy market, the DAX-listed group performed better than analysts expected in the third quarter. Sales rose by 12% to EUR 21.9 billion. EBIT (after special items) of EUR 1.29 billion was down on the prior-year quarter (Q3 2021: EUR 1.82 billion), but the profit is still decent. EBIT (before special items) of between EUR 6.8 billion and EUR 7.2 billion is forecast for fiscal 2022. If the worst-case scenario with blackout and long winter does not materialize, BASF, with a market capitalization of EUR 45 billion, is anything but expensive. However, the share price has also risen by over 30% within a few weeks.

    Therefore, analysts are currently cautious. Only yesterday, Baader Bank warned against write-downs. In the analysts' view, the high inventory levels and poor economic outlook will likely lead to high write-downs in the chemical sector. Should BASF have to close parts of its Ludwigshafen plant temporarily, high write-downs would be unavoidable. Jefferies is also cautious. The analysts rate BASF shares as "hold" with a price target of EUR 49. They, too, fear that the current quarter will be challenging in the chemical industry.

    Stock market analysts are hoping for a good year in 2023. Numerous study results are pending at BioNTech. If these turn out to be predominantly positive, further increases in the share price are likely. 2023 will also be important for Manuka Resources. In the first months of 2023, there will be news about the gold project. In addition, vanadium will come more and more into focus. BASF is more dependent on external factors such as the gas price and the global economy.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST

    70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!

    • Mining
    • Tungsten
    • hightech
    • chemicals
    • Biotechnology

    Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?


    Commented by Armin Schulz on July 23rd, 2024 | 06:45 CEST

    Plug Power, Saturn Oil + Gas, RWE - Which energy belongs in the portfolio?

    • Mining
    • Oil
    • renewableenergies
    • Energy

    The debate about the ideal energy source for the future focuses on hydrogen, oil, and renewable energies. Despite its controversial reputation, oil remains a significant energy source due to its high energy density and well-established infrastructure. Technological advances are also reducing the negative environmental impact. However, renewable energies and hydrogen also offer significant advantages, such as sustainability and low emissions. However, there is a lack of infrastructure to fully exploit the advantages of these technologies. We examine one candidate from each sector and where they stand today.


    Commented by André Will-Laudien on July 22nd, 2024 | 07:00 CEST

    Despite the super disaster with CrowdStrike, 100% returns are possible with TUI, Lufthansa, Prismo Metals and BayWa!

    • Mining
    • Commodities
    • PreciousMetals
    • IT
    • Software
    • Travel

    The CrowdStrike outage shows us just how dependent the world has become on multinational corporations from America. Within hours, everything came to a standstill - nothing worked at airports, supermarkets, and banks, and some hospitals had to postpone operations. Does this make those responsible think about what urgently needs to be changed? In addition to a completely dependent situation in the IT sector, Europe, in particular, is in a pretty poor state regarding raw materials. Chancellor Scholz is looking for resources in Serbia, a country that would like to join the EU but is closer to the aggressor Vladimir Putin. Can Brussels overlook such facts and transfer billions more to Ukraine at the same time? Europe's needs are obviously manifold, and the most urgent need is likely to master the energy transition to prevent industry migration to more favourable jurisdictions. Investors are currently facing enormous challenges. We provide some ideas for a 100% portfolio.